Citations

Clear

941 citation(s) found for "Tefferi, A".

Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: A collaborative study of 1027 patients
Tefferi, Ayalew , Wassie, Emnet A, Guglielmelli, Paola , Gangat, Naseema , Belachew, Alem A. , Finke, Christy M. , Ketterling, Rhett P. , Hanson, Curtis A. , Pardanani, Animesh , Wolanskyj, Alexandra P. , Maffioli, Margherita , Casalone, Rosario , Pacilli, Annalisa , Passamonti, Francesco , Lasho, Terra L. , Vannucchi, Alessandro M. , Wolanskyj-Spinner, Alexandra P , Ketterling, Rhett P , Passamonti, Francesco , Guglielmelli, Paola

Mayo Clinic

American Journal of Hematology | April 19, 2014 | Volume: 89 | Issue: 8 | Pages: No page available

10.1002/ajh.23743 | PMID 24753125 Get It

CALR (calreticulin) trails JAK 2 as the second most mutated gene in essential thrombocythemia (ET). Mutant CALR in ET is a result of frameshift mutations, caused by exon 9 deletions or insertions; type‐1, 52‐bp deletion (p.L367fs*46), and type‐2, 5‐bp TTGTC insertion (p.K385fs*47) variants constitute more than 80% of these mutations. The current study includes a total of 1027 patients divided into test ( n = 402) and validation ( n = 625) cohorts. Among the 402 ET patients in the test cohort, 227 (57%) harbored JAK 2, 11 (3%) Myeloproliferative leukemia virus oncogene ( MPL ), and 114 (28%) CALR mutations; 12% were wild‐type for all three mutations (i.e., triple‐negative). Among the 114 patients with CALR mutations, 51 (45%) displayed type‐1 and 44 (39%) type‐2 variants; compared to mutant JAK 2, both variants were associated with higher platelet and lower hemoglobin and leukocyte counts. However, male sex was associated with only type‐1 ( P = 0.005) and younger age with type‐2 ( P = 0.001) variants. Notably, platelet count was significantly higher in type‐2 vs. type‐1 CALR ‐mutated patients ( P = 0.03) and the particular observation was validated in the validation cohort that included 111 CALR ‐mutated ET patients ( P = 0.002). These findings, coupled with the recent demonstration of preferential expression of mutant and wild‐type CALR in megakaryocytes, suggest differential effects of CALR variants on thrombopoiesis. Am. J. Hematol. 89:E121–E124, 2014. © 2014 Wiley Periodicals, Inc.
Discriminating between essential thrombocythemia and masked polycythemia vera in JAK2 mutated patients
Barbui, Tiziano , Thiele, Jürgen, Carobbio, Alessandra , Guglielmelli, Paola , Rambaldi, Alessandro , Tefferi, Ayalew , Vannucchi, Alessandro M. , Rambaldi, Alessandro , Guglielmelli, Paola

Mayo Clinic

American Journal of Hematology | February 18, 2014 | Volume: 89 | Issue: 6 | Pages: 588-590

10.1002/ajh.23694 | PMID 24535932 Get It

In patients not meeting the required hematocrit (HCT) or hemoglobin (Hb) thresholds according to BCSH and the WHO diagnostic criteria, the diagnosis of masked polycythemia vera (mPV) has been proposed. A comparison of HCT or Hb values with the expression of JAK2V617F, JAK2 exon 12, and CALR mutations in strictly WHO‐defined 257 overt PV and 140 mPV (59 mPV according to BCSH) and 397 patients with essential thrombocythemia (ET) was performed. Hb and HCT thresholds of mPV patients were significantly higher than JAK2V617F ET (P < 0.0001). The best cut‐off for Hb to discriminate JAK2‐mutated ET from PV was 16.5 g/dL for males and 16.0 g/dL for females. For HCT, this was 49% in males and 48% in females. The proportion of patients correctly classified as ET or PV when regarding Hb or HCT levels was 95% in males and 93% in females and 94% in both males and females, respectively. Am. J. Hematol. 89:588–590, 2014. © 2014 Wiley Periodicals, Inc.
Chronic myelomonocytic leukaemia: a concise clinical and pathophysiological review
Patnaik, Mrinal M. , Hanson, Curtis A. , Tefferi, Ayalew , Parikh, Sameer A.

Mayo Clinic

British Journal of Haematology | January 28, 2014 | Volume: 165 | Issue: 3 | Pages: 273-286

10.1111/bjh.12756 | PMID 24467717 Get It

SummaryChronic myelomonocytic leukaemia (CMML) is a clonal haematopoietic stem cell disorder with myelodysplastic and myeloproliferative overlap features, and an inherent tendency to transform to acute myeloid leukaemia. Approximately 30% of patients present with clonal cytogenetic abnormalities, while almost 90% have molecular aberrations involving epigenetic regulation, the spliceosome component machinery, tumour suppressor genes and transcription factors/regulators. Numerous prognostic models exist for CMML, with more recent models incorporating prognostic mutations, such as those involving ASXL1. Other variables that seem to consistently affect outcomes include the degree of leucocytosis/monocytosis, anaemia and thrombocytopenia. Allogeneic stem cell transplant remains the only curative option for CMML, while hypomethylating agents can be used for transplant‐ineligible patients or those without suitable stem cell sources. Targeting biological pathways activated in CMML offers potential hope for more effective and less toxic therapies.
CALR mutation studies in chronic neutrophilic leukemia
Elliott, Michelle A. , Pardanani, Animesh , Tefferi, Ayalew , Lasho, Terra L.

Mayo Clinic

American Journal of Hematology | January 13, 2014 | Volume: 89 | Issue: 4 | Pages: 450-450

10.1002/ajh.23665 | PMID 24421250 Get It

Masked polycythemia vera diagnosed according to WHO and BCSH classification
Barbui, Tiziano , Thiele, Jürgen, Carobbio, Alessandra , Gisslinger, Heinz , Rumi, Elisa , Randi, Maria Luigia , Gisslinger, Bettina, Müllauer, Leonhard , Ruggeri, Marco , Rambaldi, Alessandro , Tefferi, Ayalew , Finazzi, Guido , Vannucchi, Alessandro M. , Rambaldi, Alessandro

Mayo Clinic

American Journal of Hematology | October 26, 2013 | Volume: 89 | Issue: 2 | Pages: 199-202

10.1002/ajh.23617 | PMID 24166817 Get It

Polycythemia vera (PV) is currently diagnosed by the World Health Organization (WHO) criteria regarding hemoglobin (HB) levels and JAK2V617F and related mutations or by the British Committee for Standards in Haematology (BCSH) guidelines predominantly based on hematocrit (HCT) values (>52% in men and >48% in women) in JAK2 mutated patients. We examined clinical features at diagnosis and outcome in 397 mutated PV patients showing a bone marrow (BM) morphology conforming with the WHO descriptions but including also cases with a HB level <18.5 g/dL in males (range 16.0–18.4) and <16.5 g/dL in females (range 15.0–16.4). These patients were regarded as masked PV (mPV) comprising 140 (35%) cases of our cohort. A comparison with the BCSH criteria based on HCT levels revealed a decrease of mPV patients to 59 (15%). In both classification systems, mPV patients were more males, presented more frequently with higher platelet counts, and increased BM reticulin fibrosis. A worsening of overall survival was documented in mPV patients in comparison with overt PV following the WHO (P = 0.011) as well as the BCSH (P = 0.0019) criteria. Risk factors for inferior survival in mPV were age >65 years and white blood cell count >15 × 109/L. Without these risk factors mPV patients had the same survival as overt PV suggesting that a fraction of patients with HB lower than that required for WHO diagnosis should still be considered as overt PV. This study has established the existence of mPV by two different classification systems based on either HB or HCT threshold values. Am. J. Hematol. 89:199–202, 2014. © 2013 Wiley Periodicals, Inc.
Masked polycythemia Vera (mPV): Results of an international study
Barbui, Tiziano , Thiele, Jürgen, Gisslinger, Heinz , Carobbio, Alessandra , Rumi, Elisa , Randi, Maria Luigia , Betozzi, Irene, Pieri, Lisa , Carrai, Valentina , Gisslinger, Bettina, Müllauer, Leonhard , Ruggeri, Marco , Rambaldi, Alessandro , Tefferi, Ayalew , Finazzi, Guido , Vannucchi, Alessandro M. , Rambaldi, Alessandro

Mayo Clinic

American Journal of Hematology | August 31, 2013 | Volume: 89 | Issue: 1 | Pages: 52-54

10.1002/ajh.23585 | PMID 23996471 Get It

We examined the baseline features and clinical outcomes of 140 patients presenting with JAK2V617F positivity and a bone marrow morphology conforming with WHO criteria of polycythemia vera (PV), but a hemoglobin level of <18.5 g/dL in males (range 16.0–18.4) and <16.5 g/dL in females (range 15.0–16.4). This cohort operationally referred to as masked PV (mPV) was compared with 257 patients with overt PV and displayed male predominance, a more frequent history of arterial thrombosis and thrombocytosis. Incidence of thrombosis was similar between the two groups but mPV displayed significantly higher rates of progression to myelofibrosis and acute leukemia and inferior survival. In multivariable analysis mPV diagnosis was an independent predictor of poor survival along with age >65 years and leukocyte count >10 × 109/L. Our data suggest that mPV is a heterogeneous myeloproliferative neoplasia and not necessarily an early/ pre‐polycythemic form of classical PV that at onset in a small fraction of patients clinically may mimic essential thrombocythemia. On the other hand, the majority mPV may have a longer prodrome of undiagnosed PV or a disease biology akin to primary myelofibrosis‐post PV myelofibrosis that could explain the worsening of outcome in comparison to overt/classical manifestations. Am. J. Hematol. 89:52–54, 2014. © 2013 Wiley Periodicals, Inc.
Chronic myelomonocytic leukemia: 2013 update on diagnosis, risk stratification, and management
Tefferi, Ayalew , Parikh, Sameer A.

Mayo Clinic

American Journal of Hematology | August 20, 2013 | Volume: 88 | Issue: 11 | Pages: 967-974

10.1002/ajh.23574 | PMID 23963888 Get It

Disease overviewChronic myelomonocytic leukemia (CMML) is a clonal hematopoietic stem cell disorder that is classified as a myelodysplastic/myeloproliferative neoplasm by the 2008 World Health Organization classification of hematopoietic tumors. It is characterized by absolute monocytosis (>1 × 109/L) in the peripheral blood that persists for at least 3 months.DiagnosisThe diagnosis of CMML rests on a combination of morphologic, histopathologic and chromosomal abnormalities in the bone marrow. It is important to exclude other myeloproliferative neoplasms and infectious/autoimmune conditions that can cause monocytosis.Risk stratificationSeveral CMML‐specific prognostic models incorporating novel mutations have been recently reported. The Mayo prognostic model classified CMML patients into three risk groups based on: increased absolute monocyte count, presence of circulating blasts, hemoglobin <10 gm/dL and platelets <100 × 109/L. The median survival was 32 months, 18.5 months and 10 months in the low, intermediate, and high‐risk groups, respectively. The Groupe Francophone des (GFM) score segregated CMML patients into three risk groups based on: age >65 years, WBC >15 × 109/L, anemia, platelets <100 × 109/L, and ASXL1 mutation status. After a median follow‐up of 2.5 years, survival ranged from not reached in the low‐risk group to 14.4 months in the high‐risk group.Risk‐adapted therapyThe Food and Drug Administration has approved azacitidine and decitabine for the treatment of patients with CMML. An allogeneic stem cell transplant can potentially offer a curative option to a subset of CMML patients. It is hoped that with the discovery of several novel mutations, targeted therapies will become available in the near future. Am. J. Heamtol. 88:968–974, 2013. © 2013 Wiley Periodicals, Inc.
Ruxolitinib targets DCs: for better or worse?
Tefferi, Ayalew

Mayo Clinic

Blood | August 15, 2013 | Volume: 122 | Issue: 7 | Pages: 1096-1097

10.1182/blood-2013-07-509612 | PMID 23950171 Get It

Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report
Tefferi, Ayalew , Cervantes, Francisco , Passamonti, Francesco , Verstovšek, Srđan , Dupriez, Brigitte, Pardanani, Animesh , Harrison, Claire , Gisslinger, Heinz , Thiele, Jüergen, Barbui, Tiziano , Mesa, Ruben A. , Vannucchi, Alessandro M. , Gotlib, Jason , Hoffman, Ronald , Kröger, Nicolaus , Barosi, Giovanni , Verstovsek, Srdan , Passamonti, Francesco

Mayo Clinic

Blood | July 9, 2013 | Volume: 122 | Issue: 8 | Pages: 1395-1398

10.1182/blood-2013-03-488098 | PMID 23838352 Get It

Key Points Treatment response criteria for MF must capture drug benefit in terms of symptom burden. The current document includes stricter definitions of red cell transfusion need and independence.
Identification of submicroscopic genetic changes and precise breakpoint mapping in myelofibrosis using high resolution mate‐pair sequencing
Johnson, Sarah H. , Smith, David I., Crispino, John D. , Pardanani, Animesh , Vasmatzis, George , Tefferi, Ayalew , Lasho, Terra L. , Smith, David I., Crispino, John D

Mayo Clinic

American Journal of Hematology | June 4, 2013 | Volume: 88 | Issue: 9 | Pages: 741-746

10.1002/ajh.23495 | PMID 23733509 Get It

We used high resolution mate‐pair sequencing (HRMPS) in 15 patients with primary myelofibrosis (PMF): eight with normal karyotype and seven with PMF‐characteristic cytogenetic abnormalities, including der(6)t(1;6)(q21–23;p21.3) (n = 4), der(7)t(1;7)(q10;p10) (n = 2), del(20)(q11.2q13.3) (n = 3), and complex karyotype (n = 1). We describe seven novel deletions/translocations in five patients (including two with normal karyotype) whose breakpoints were PCR‐validated and involved MACROD2, CACNA2D4, TET2, SGMS2, LRBA, SH3D19, INTS3, FOP (CHTOP), SCLT1, and PHF17. Deletions with breakpoints involving MACROD2 (lysine deacetylase; 20p12.1) were recurrent and found in two of the 15 study patients. A novel fusion transcript was found in one of the study patients (INTS3‐CHTOP), and also in an additional non‐study patient with PMF. In two patients with der(6)t(1;6)(q21–23;p21.3), we were able to map the precise translocation breakpoints, which involved KCNN3 and GUSBP2 in one case and HYDIN2 in another. This study demonstrates the utility of HRMPS in uncovering submicroscopic deletions/translocations/fusions, and precise mapping of breakpoints in those with overt cytogenetic abnormalities. The overall results confirm the genetic heterogeneity of PMF, given the low frequency of recurrent specific abnormalities, identified by this screening strategy. Currently, we are pursuing the pathogenetic relevance of some of the aforementioned findings. Am. J. Hematol. 88:741–746, 2013. © 2013 Wiley Periodicals, Inc.